Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

84.85 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 84.85
Bid (Size) 81.23 (2)
Ask (Size) 98.00 (1)
Prev. Close 84.85
Today's Range 84.85 - 84.85
52wk Range 73.67 - 99.56
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-13.46%
-13.46%
1 Month
-4.70%
-4.70%
3 Month
+1.17%
+1.17%
6 Month
-0.39%
-0.39%
1 Year
-6.61%
-6.61%

More News

Read More
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
Via Benzinga
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
Via Chartmill
NASDAQ:BMRN is showing good growth, while it is not too expensive.
Via Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
Via Talk Markets
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
Via Chartmill
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Via Benzinga
Peering Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Via Benzinga
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
Via Benzinga
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Via Benzinga
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Via Benzinga
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via Chartmill
CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.